XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Operating activities:    
Net loss $ (434,172) $ (370,463)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 79,731 46,313
Depreciation and amortization 4,317 1,021
Noncash lease expense 4,078 2,169
Accretion of debt 4,043 12,315
LEO call option expense (income) (5,550) 1,120
Other noncash adjustments 8,513 4,134
Changes in operating assets and liabilities:    
Receivable from licensing and collaboration agreements (7,710)  
Receivable from a related party (462) (5,155)
Prepaid expenses and other current assets (3,743) (5,391)
Other assets (8,930) (194)
Accounts payable 1,360 547
Accrued compensation and benefits (4,443) 2,395
Accrued research and development liabilities 4,686 4,004
Accrued professional services 346 1,151
Operating lease liabilities (4,474) (2,309)
Other accrued and other long-term liabilities (1,629) 4,890
Net cash used in operating activities (364,039) (303,453)
Investing activities    
Purchases of marketable securities (575,478) (269,802)
Maturities of marketable securities 305,200 139,016
Sales of marketable securities 98,925  
Purchases of investment in equity securities (23,960)  
Sales of investment in equity securities 4,743  
Increase in cash and cash equivalents from consolidation of PellePharm 13,654  
Acquisition of intangible assets (35,000)  
Proceeds from disposal of property and equipment   147
Purchases of property and equipment (10,710) (5,372)
Net cash used in investing activities (222,626) (136,011)
Financing activities    
Proceeds from issuance of 2029 Notes in 2021 and 2027 Notes in 2020 747,500 550,000
Issuance costs and discounts associated with issuance of 2029 Notes and 2027 Notes (16,064) (13,039)
Purchase of capped calls (61,295) (49,280)
Repurchases of common stock (198,458) (75,000)
Proceeds from at-the-market issuance of noncontrolling interest by Eidos, net   24,094
Transactions with noncontrolling interests 3,500 2,000
Repurchase of Eidos noncontrolling interest, including direct transaction costs (85,090)  
Proceeds from term loan 25,000  
Repayment of term loan (18,108)  
Proceeds from BridgeBio common stock issuances under ESPP 3,821 1,205
Repurchase of shares to satisfy tax withholding (4,035) (243)
Proceeds from stock option exercises, net of repurchases 14,294 2,921
Net cash provided by financing activities 411,065 442,658
Net increase (decrease) in cash, cash equivalents and restricted cash (175,600) 3,194
Cash, cash equivalents and restricted cash at beginning of period 358,679 364,197
Cash, cash equivalents and restricted cash at end of period 183,079 367,391
Supplemental Disclosures of Cash Flow Information:    
Cash paid for interest 28,239 13,281
Supplemental Disclosures of Noncash Investing and Financing Information:    
Net noncash portion of repurchase of Eidos noncontrolling interests 38,167  
Direct transaction costs in the repurchase of Eidos recorded in "Additional paid-in capital" previously classified in "Prepaid expenses and other current assets" 8,749  
Noncash contribution by noncontrolling interest 21,600  
Deferred merger transaction costs included in Accounts payable and Accrued professional services   1,527
Recognized intangible asset recorded in Other accrued liabilities and Other long-term liabilities 12,500  
Leasehold improvements paid by landlord 2,449  
Repurchase of common stock recorded in Accounts payable 1,542  
Recognition of property and equipment previously classified in other assets   10,000
Transfers from (to) noncontrolling interests (Note 6) $ (221) $ 9,572